Gilead Sciences, Inc. (GILD) - Yahoo Finance
Find the latest Gilead Sciences, Inc. (GILD) stock quote, history, news and other vital information to help you with your stock trading and investing.
Gilead’s Twice-Yearly Lenacapavir Demonstrated 100% Efficacy …
FOSTER CITY, Calif., June 20, 2024 -- (BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from an interim analysis of its pivotal, Phase 3 PURPOSE 1 trial...
Gilead Sciences: Finally Some Real Momentum - Seeking Alpha
4 days ago · Gilead Sciences, Inc. has seen growth return to the HIV franchise and the liver business. Click here to read my GILD stock update. ... Amidst this news, shares fell to the $70 mark, trading at 10 ...
Gilead Sciences, Inc. (GILD) Latest Stock News & Headlines
Get the latest Gilead Sciences, Inc. (GILD) stock news and headlines to help you in your trading and investing decisions.
Gilead Sciences Expands Liver Portfolio With Acquisition of …
Feb 12, 2024 · FOSTER CITY, Calif. & NEWARK, Calif.-- (BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) and CymaBay Therapeutics, Inc. (Nasdaq: CBAY) announced today a definitive agreement under which Gilead will acquire CymaBay for $32.50 per share in cash or a total equity value of $4.3 billion.
Gilead Sciences Announces Fourth Quarter and Full Year 2023 …
Feb 6, 2024 · Biktarvy® (bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 7% to $3.1 billion in the fourth quarter 2023 compared to the same period in 2022, primarily reflecting higher demand, partially offset by lower average realized price due to channel mix.
Gilead Provides Update on Phase 3 EVOKE-01 Study - Gilead Sciences
Jan 22, 2024 · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Phase 3 EVOKE-01 study did not meet its primary endpoint of overall survival (OS) in previously treated metastatic non-small cell lung cancer (NSCLC).
Gilead Sciences, Inc. (GILD) Stock Price & News - Google
Get the latest Gilead Sciences, Inc. (GILD) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.
Gilead Sciences (GILD) Presents Full PURPOSE 2 Data Results for …
5 hours ago · Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial (NCT04925752), which is studying twice-yearly lenacapavir, the ...
Gilead Sciences, Inc. - Late-Breaking Clinical Data and Real-World ...
6 days ago · FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2024), taking place from November 10-13.The results from more than 40 studies across HIV treatment and prevention include late …